ArticleNanomedicine (London, England)2025
A multimodal approach to smart and sustained drug delivery for corneal wound management: the GelPol nanoformulation.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to develop a thermo-photo dual-stimuli-responsive hydrogel matrix and ROS-responsive engineered nanocarriers-based composite GelPol nanoformulation for corneal wound management. GelPol is composed of modified gelatin and poloxamer 407SH holding nanoparticles (NPs) loaded with dexamethasone, rapamycin, and ciprofloxacin. RESEARCH DESIGN AND
methodsDual-stimuli-responsive hydrogel and ROS-responsive NPs were synthesized and characterized. Sol-gel transition of GelPol was studied at various temperatures and light irradiation. In vitro release studies and kinetics from the GelPol nanoformulation were conducted at 25°C and 37°C over 3 weeks. Structural integrity and stability studies were performed under various conditions (temperature and pH) for 4 weeks and confirmed through FTIR and DSC analyses. Cell viability and biocompatibility studies using HCEC were conducted to assess safety.
resultsThe NPs characterization revealed hydrodynamic diameters ranging from 105 to 114 nm with polydispersity between 0.108 and 0.153. Encapsulation efficiencies for DEX, RAPA, and CIP were 87.27%, 88.11%, and 76.94%, respectively. Stability studies confirmed the GelPol stability through FTIR, DSC, and HPLC analyses. Cell viability and biocompatibility studies demonstrated the safety of GelPol formulations.
conclusionsThe tailored GelPol novel approach could offer a noninvasive alternative for corneal wound treatment, potentially improving patient safety and adherence compared to traditional procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.